文献速递主动脉疾病

主治医师改良腔内移植物治疗近肾腹主动脉瘤后的再干预对长期生存无不良影响

Reinterventions after physician-modified endovascular grafts for treatment of juxtarenal aortic aneurysms are non-detrimental to long-term survival.
PubMed 文献 · J Vasc Surg · 2023-01-07

基于前瞻性器械豁免临床试验(NCT01538056,2011—2022年)170例近肾腹主动脉瘤行主治医师改良腔内移植物(PMEG)的患者,50例(29%)共接受91次再干预,1年与5年免于再干预率分别为84%与60%;再干预与未再干预者生存无差异,但PMEG后1周内再干预与死亡风险升高相关(对比晚期再干预HR 11.1,对比无再干预HR 5.2)。作者认为再干预对长期生存无不良影响,但早期再干预与死亡风险升高相关,应预期一定频率的再干预并重视终身监测。

要点

  • 再干预以经皮(80%)、轻微(55%)、低生理影响(77%)为主,最常见为肾动脉支架置入(26%)。
  • 再干预与未再干预患者生存无差异,但PMEG后1周内再干预与死亡风险升高相关。
  • 作者认为PMEG后应预期适度频率的再干预,强调终身监测的重要性。

核心结论

  • PMEG后再干预最常见为经皮、轻微、低生理影响的操作,对长期生存无不良影响;但早期再干预与死亡风险升高相关。
  • 作者认为PMEG后应预期适度频率的再干预,强调终身监测的至关重要性。

研究设计与样本

  • 前瞻性器械豁免临床试验(注册号NCT01538056)2011—2022年数据,共170例近肾腹主动脉瘤患者接受PMEG。

主要发现

  • 170例中50例(29%)共接受91次再干预,平均每例1.8次。
  • 1年免于再干预率为84%,5年免于再干预率为60%。
  • 再干预中经皮占80%、轻微占55%、低生理影响占77%,最常见为肾动脉支架置入(26%)。
  • PMEG后1周内早期再干预共10次,再干预后发生2例主动脉相关死亡。
  • 再干预与未再干预患者生存无差异;校正分析后,PMEG后1周内再干预对比晚期再干预死亡风险HR 11.1(95%CI 2.7-46.5),对比无再干预HR 5.2(95%CI 1.6-16.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Reintervention after endovascular aortic aneurysm repair is common. However, their frequency and impact on mortality after physician-modified endografts (PMEGs) is unknown. This study aims to describe reinterventions after PMEG for treatment of juxtarenal aneurysms and their effect on survival. METHODS: Data from a prospective investigational device exemption clinical trial (Identifier #NCT01538056) from 2011 to 2022 were used. Reinterventions after PMEG were categorized as open or percutaneous and major or minor by Society for Vascular Surgery reporting standards and as high or low magnitude based on physiologic impact. Reinterventions were also categorized by timing, based on whether they occurred within 30 days of PMEG as well as within 1 week of PMEG. Survival was compared between patients who did and did not undergo reintervention and between reintervention subcategories. RESULTS: A total of 170 patients underwent PMEG, 50 (29%) of whom underwent a total of 91 reinterventions (mean reinterventions/patient, 1.8). Freedom from reintervention was 84% at 1 year and 60% at 5 years. Reinterventions were most often percutaneous (80%), minor (55%), and low magnitude (77%), and the most common reintervention was renal stenting (26%). There were 10 early reinterventions within 1 week of PMEG. Two aortic-related mortalities occurred after reintervention. There were no differences in survival between patients who underwent reintervention and those who did not. However, survival differed based on the timing of reintervention. After adjusted analysis, reintervention within one week of PMEG was associated with an increased risk of mortality both compared with late reintervention (hazard ratio, 11.1; 95% confidence interval, 2.7-46.5) and no reintervention (hazard ratio, 5.2; 95% confidence interval, 1.6-16.8). CONCLUSIONS: Reinterventions after PMEG were most commonly percutaneous, minor, and low magnitude procedures, and non-detrimental to long-term survival. However, early reinterventions were associated with increased mortality risk. These data suggest that a modest frequency of reinterventions should be expected after PMEG, emphasizing the critical importance of lifelong surveillance.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tachida A, Stafforini N, Singh N, et al. Reinterventions after physician-modified endovascular grafts for treatment of juxtarenal aortic aneurysms are non-detrimental to long-term survival. J Vasc Surg. 2023. PMID: 36626956. doi:10.1016/j.jvs.2022.12.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。